Overview

Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors

Status:
Terminated
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, Phase Ib dose-escalation study designed to assess the safety, tolerability and pharmacokinetics of oral dosing of cobimetinib and pictilisib administered in combination in patients with locally advanced or metastatic solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Genentech, Inc.